A number of investment brokers have recently updated their price targets on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS).

Most recent broker ratings

03/16/2016 – Aclaris Therapeutics, Inc. had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 29 price target on the stock.

11/02/2015 – William Blair began new coverage on Aclaris Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 30 price target on the stock.

11/02/2015 – Jefferies began new coverage on Aclaris Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 20 price target on the stock.

The share price of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) was down -1.47% during the last trading session, with a day high of 21.38. 27078 shares were traded on Aclaris Therapeutics, Inc.’s last session.

The stock’s 50 day moving average is 19.02 and its 200 day moving average is 19.84. The stock’s market capitalization is 417.45M. Aclaris Therapeutics, Inc. has a 52-week low of 10.99 and a 52-week high of 33.88.

View other investors thoughts on Aclaris Therapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.